Quarterly ResultMay 15, 2026, 04:24 PM
Transcode Therapeutics Q1 Net Loss $(17.8)M; Going Concern Doubt
AI Summary
Transcode Therapeutics reported a net loss of $(17.8) million for the three months ended March 31, 2026, an increase from $(12.1) million in the prior year period. The company's cash balance decreased to $12.8 million, and it explicitly stated substantial doubt about its ability to continue as a going concern, with current funds expected to last only until approximately year-end 2026. This follows the October 2025 acquisition of ABCJ, LLC (Polynoma) and a $25 million investment, as well as the recent issuance of Series C Preferred Stock for a licensing agreement.
Key Highlights
- Net loss for Q1 2026 was $(17.8) million, up from $(12.1) million in Q1 2025.
- Cash balance at March 31, 2026, was $12.8 million, down from $17.8 million at Dec 31, 2025.
- Net cash used in operating activities increased to $(5.0) million in Q1 2026.
- Acquired in-process research and development expense totaled $10.4 million for the quarter.
- Company has substantial doubt about its ability to continue as a going concern.
- Current cash and expected reimbursement are sufficient only until approximately year-end 2026.
- Issued Series C Preferred Stock in connection with a licensing agreement with Unleash Immuno Oncolytics.
Price Impact
More from RNAZ